1616064-77-7

Basic information

• Product Name: (R)-2-(oxiran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline
• Synonyms: (R)-2-(oxiran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline
• CAS NO: 1616064-77-7
• Molecular Formula: C₁₂H₁₅NO
• Molecular Weight: 189.2536
• Mol File: 1616064-77-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-2-(oxiran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-(oxiran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline(1616064-77-7)
• EPA Substance Registry System: (R)-2-(oxiran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline(1616064-77-7)

Safety Data

• Hazardous Substances Data: 1616064-77-7(Hazardous Substances Data)

Usage

General Description

(R)-2-(oxiran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline is a chemical compound that belongs to the class of tetrahydroisoquinoline derivatives. It contains a tetrahydroisoquinoline core with a substituent of (R)-2-(oxiran-2-ylmethyl) at the second position. (R)-2-(oxiran-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline has potential pharmacological properties and is of interest in medicinal chemistry research. It may have applications in the development of new drugs for various therapeutic purposes, such as in the treatment of neurological disorders or as a potential anticancer agent. Further research is needed to fully understand the pharmacological and biological activities of this compound and to explore its potential as a drug candidate.

Upstream product

• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 51594-55-9 (R)-(-)-epichlorohydrin 
• 67843-74-7 (S)-epichlorohydrin 
• 115314-14-2 (2s)-(+)-glycidyl 3-nitrobenzenesulfonate 
• 115314-14-2 (R)-glycidyl nosylate 

Downstream Products

• 1616064-59-5 (R)-1-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-4-(phenylamino)pyridin-2(1H)-one 
• 1616064-78-8 (R)-4-bromo-1-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyridin-2(1H)-one 
• 1616077-51-0 (S)-1-amino-3-(3,4-dihydroisoquinolin-2(1H)-yl)-propan-2-ol 
• 1616246-32-2 (S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-3-((tetrahydro-2H-pyran-4-yl)amino)benzamide 
• 1616391-87-7 GSK591 
• 1616246-07-1 (S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-3-(pyridin-2-yl)benzamide 
• 1616392-22-3 GSK-3326595 

Relevant articles and documents

A Flow Process Built upon a Batch Foundation - Preparation of a Key Amino Alcohol Intermediate via Multistage Continuous Synthesis

This paper describes recent efforts to apply flow technology in the preparation of the key amino alcohol intermediate 3b so as to address manufacturability issues present in the batch process of a PRMT5 inhibitor. The continuous process, one of the first reported pharmaceutical processes to use aqueous NH4OH in flow, eliminates an isolation and the use of dichloromethane in the workup and improves reaction time >140-fold compared with the batch process to deliver multigram quantities of 3b in 60-65% isolated yield with >99 HPLC area % and >99% ee. While the flow process greatly increases the efficiency compared with the batch process, small-scale batch experiments were crucial in gaining reaction understanding to increase the kinetics and minimize impurity formation. The holistic process design underscores our belief that large-scale flow processes are built upon the knowledge gained through well-chosen small-scale batch experiments.

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.

SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS

The present invention relates to substituted imidazolidin-2-one derivatives of formula (I) or pharmaceutically acceptable salts thereof. The present invention further provides the methods of preparation of compound of formula (I) and utility as PRMT5 inhibitors. The compounds are useful as medicaments in the treatment of conditions and disorders mediated by PRMT5, such as cancer, metabolic disorders, inflammation, autoimmune disease and hemoglobinopathies.